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Abstract
Background: Opioidergic SLP (sustained ligand-activated preconditioning) induced by 3–5 days of opioid receptor (OR)
agonism induces persistent protection against ischemia-reperfusion (I-R) injury in young and aged hearts, and is
mechanistically distinct from conventional preconditioning responses. We thus applied unbiased gene-array interrogation
to identify molecular effects of SLP in pre- and post-ischemic myocardium.
Methodology/Principal Findings: Male C57Bl/6 mice were implanted with 75 mg morphine or placebo pellets for 5 days.
Resultant SLP did not modify cardiac function, and markedly reduced dysfunction and injury in perfused hearts subjected to
25 min ischemia/45 min reperfusion. Microarray analysis identified 14 up- and 86 down-regulated genes in normoxic hearts
from SLP mice ($1.3-fold change, FDR#5%). Induced genes encoded sarcomeric/contractile proteins (Myh7,
Mybpc3,Myom2,Des), natriuretic peptides (Nppa,Nppb) and stress-signaling elements (Csda,Ptgds). Highly repressed genes
primarily encoded chemokines (Ccl2,Ccl4,Ccl7,Ccl9,Ccl13,Ccl3l3,Cxcl3), cytokines (Il1b,Il6,Tnf) and other proteins involved in
inflammation/immunity (C3,Cd74,Cd83, Cd86,Hla-dbq1,Hla-drb1,Saa1,Selp,Serpina3), together with endoplasmic stress
proteins (known: Dnajb1,Herpud1,Socs3; putative: Il6, Gadd45g,Rcan1) and transcriptional controllers (Egr2,Egr3,
Fos,Hmox1,Nfkbid). Biological themes modified thus related to inflammation/immunity, together with cellular/cardiovascular
movement and development. SLP also modified the transcriptional response to I-R (46 genes uniquely altered post-
ischemia), which may influence later infarction/remodeling. This included up-regulated determinants of cellular resistance
to oxidant (Mgst3,Gstm1,Gstm2) and other forms of stress (Xirp1,Ankrd1,Clu), and repression of stress-response genes
(Hspa1a,Hspd1,Hsp90aa,Hsph1,Serpinh1) and Txnip.
Conclusions: Protection via SLP is associated with transcriptional repression of inflammation/immunity, up-regulation of
sarcomeric elements and natriuretic peptides, and modulation of cell stress, growth and development, while conventional
protective molecules are unaltered.
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Introduction
Adjunctive cardioprotective therapy to limit myocardial damage
and death during infarction or surgical I-R in ischemic heart
disease (IHD) patients remains an important though elusive
clinical goal [1]. IHD is the leading cause of death and healthcare
expenditure in Australia, and is predicted to remain the leading
global health problem in coming decades, emerging as a major
issue in both developing and developed countries [2]. With
population aging the impact of IHD will rise, with growing
incidences of diabetes, obesity, dyslipidemia, and hypertension
further contributing to IHD prevalence. Despite the enormity of
this problem, we still have no clinically effective cardioprotective
therapies to improve short- or long-term outcomes from myocar-
dial ischemia, beyond essential (and timely) reperfusion. This
reflects in part our incomplete understanding of mechanisms
governing myocardial survival vs. death, and particularly how
these are influenced by age, sex, disease and common pharma-
ceuticals [3,4]. Unfortunately, widely studied experimental stimuli
including pre- and post-conditioning may be impaired or negated
with aging [5], relevant disease states such as diabetes [6,7],
obesity [8] and hypertension/hypertrophy [9,10], and commonly
applied drugs such as ß-blockers [11] and ACE inhibitors [9].
Contrasting conventional protective responses, SLP is highly
effective in both young and aged myocardium, inducing protection
that persists for up to a week post-stimulus and that is equivalent or
superior to that with other preconditioning stimuli [12–15]. While
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potentially superior to other candidate responses, the molecular
basis of SLP remains to be elucidated. Shifts in myocardial protein
expression/localization are likely involved given that SLP requires
3–5 days of induction and generates persistent protection evident
both in vivo and ex vivo [15]. Mechanistically, SLP is distinct from
conventional protective and conditioning responses [14,15], being
Gi (pertussis toxin) insensitive and independent of well-established
mediators including PI3K/Akt, NOS, mTOR, PKC, KATP
channels and cRaf1 kinase (upstream of MEK/MAPK signaling),
whereas Gs-dependent PKA signals may contribute [14]. Given
these unique features, we here applied un-biased transcriptome-
wide interrogation to identify molecular changes associated with
novel SLP.
Results
Cardiac Response to SLP
Induction of SLP did not modify baseline contractile function or
coronary flow in isolated perfused hearts (Table 1). In terms of I-
R tolerance, hearts from SLP mice exhibited substantially
improved ventricular contractile recoveries (Figure 1). Further-
more, the extent of cellular death/damage, as indicated by post-
ischemic LDH efflux, was significantly reduced by .75% in the
SLP group (Figure 1).
Transcriptional Effects of SLP ‘‘Induction’’ in Normoxic
Myocardium
To identify molecular adaptations in SLP hearts, myocardial
gene expression was interrogated via microarray. Of 45,200
transcripts represented on the Illumina MouseWG-6 v1.1
BeadChip, 13,335 (30%) were expressed in $2 myocardial
samples per group. In normoxic myocardium SLP induction was
associated with up-regulation of 14 transcripts and repression of 86
transcripts, based on fold-changes $1.3 and a FDR of #5%
(Table S1). Induced transcripts were involved in contraction/
sarcomeric function (Myh7, Mybpc3, Myom2, Des), cardioprotec-
tion/remodeling (Nppa, Nppb), and stress signaling (Csda, Ptgds). Of
highly repressed transcripts, a majority were chemokines (Ccl2,
Ccl4, Ccl7, Ccl9, Ccl13, Ccl3l3, Cxcl3), cytokines (Il1b, Il6, Tnf), and
other inflammation/immunity related transcripts (Serpina3, Saa1,
C3, Cd74, Hla-drb1, Hla-dbq1, Selp, Cd83, Cd86), together with
endoplasmic reticulum stress response (ERSR) genes (Dnajb1,
Socs3, Herpud1, Il6, Gadd45g, Rcan1) and transcriptional controllers
(Egr2, Egr3, Fos, Hmox1, Nfkbid). We further assessed shifts in
protein expression for 2 key transcript changes - Myh7 and Nppa
(Figure 2). These data confirm Myh7 transcript induction
translates to increased myocardial MYH7 protein content (which
was below detection limits in untreated tissue, consistent with
normal expression in the neonatal myocardium), whereas induc-
tion of Nppa was not associated with a detectable increase in
cardiac ANP expression (Figure 2).
Functional annotation and interrogation via the IPA suite
identified similar themes of inflammatory/immune modulation,
regulation of cell movement, growth and development, and cell
death/survival responses (Table 2; Table S3). The top molecular
canonical functions identified included (in descending order of
significance): cell-to-cell communication and interaction, cellular
movement, antigen presentation, cellular development, cellular
function and maintenance, cellular growth and proliferation, cell
death, and cell signaling. The top represented disease processes
included: inflammatory responses, immunological disease, con-
nective tissue disorders, inflammatory disease, skeletal and
muscular disorders. These paths and functions are suggestive of
SLP-dependent control of inflammatory/immune function, cardi-
ac contraction and remodeling, and stress-responses (cell death,
survival and signaling, oxidative stress responses). Network analysis
identified 9 significantly modified networks during SLP induction,
based upon known molecular interactions (Table 3). Again, the
most significantly modified revolve around cell movement,
immune/inflammatory functions and cardiovascular disease and
development (Table 3). As detailed in Figure 3 the two top
modified networks are involved in inflammatory/immune func-
tion, network 1 centered on NfkB and Il12/chemokine responses,
and network 2 centered on TNFa and MHC/HLA responses.
The two cardiovascular-related networks identified (3 and 4) also
involve inflammatory signaling, together with processes of cellular
growth and development (Figure 4).
Transcriptional Effects of SLP in Post-Ischemic
Myocardium
Myocardial gene expression patterns following ischemic insult
will influence progression of infarction, remodeling and ultimately
failure. Post-ischemic expression patterns were significantly
modified by SLP, which led to up-regulation of 29 transcripts
and repression of 51 transcripts in reperfused myocardium (Table
S2). Of these SLP-responsive transcripts, 33 were similarly altered
by SLP pre-ischemia, whereas 46 were identified as specifically
modified by SLP post-ischemic tissue only (21 up- and 25 down-
regulated). The latter included up-regulation of transcripts
involved in cardiac stress signaling and development (Xirp1,
Ankrd1, Clu) and anti-oxidant function (Mgst3, Gstm1, Gstm2), and
repression of Txnip and heat shock transcripts (Hsph1, Hspa1a,
Hspd1, Serpinh1) (Table S2). Functional/pathway analysis of post-
ischemic transcriptional responses to SLP identified processes and
networks similar to those modified in normoxic tissue, including
inflammatory/immune signaling paths and processes, cellular
movement, growth, development, and signaling (Tables 4 and 5;
Table S4).
Select gene changes identified via microarray interrogation of
normoxic and post-ischemic myocardium were further validated
via RT-qPCR analysis. As shown in Figure 5, genes assessed by
RT-qPCR exhibited expression changes during SLP induction
that were consistent with responses detected by microarray
Table 1. Baseline function in Langendorff hearts from SLP and placebo mice.
GROUP LVEDP (mmHg) LVDP (mmHg) +dP/dt (mmHg/s) 2dP/dt (mmHg/s) Coronary Flow (ml/min/g)
5-day Placebo (n=8) 561 14869 54586487 33456256 3.060.2
5-day SLP (n= 8) 461 15067 52206363 32086210 2.960.2
Data were acquired after 30 min aerobic perfusion (at a fixed heart rate of 420 bpm). Data are means6S.E.M. There were no significant differences in baseline (pre-
ischemic) functional measures between groups. LVEDP, left ventricular end-diastolic pressure; LVDP, left ventricular developed pressure; dP/dt, differential of ventricular
pressure development or relaxation over time.
doi:10.1371/journal.pone.0072278.t001
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analysis. The very strong positive and linear correlation (r2 = 0.95)
highlights the complementarity of RT-qPCR and microarray
techniques, and thus the general quantitative value of array-
derived gene expression changes (though the slope of the
relationship reflects a superior sensitivity and dynamic range for
RT-qPCR; Figure 5). Interestingly, of this sub-set of transcrip-
tional responses specifically quantitated by PCR, pre-ischemic
induction of myocardial Myh7 and Nppa, and repression of Pdk4,
Ccl7, Fos and Il6 have not previously been reported for
cardioprotected models. Post-ischemic induction of Ankrd1 and
Xirp1 and repression of Txnip and Tlr2 have also not been linked to
cardioprotection.
Discussion
Clinically applicable interventions to limit myocardial cell death
with infarction or surgical I-R are needed [3,4]. Interventions
based on conventional pre- and post-conditioning have been
widely studied, yet may possess significant drawbacks. Notably,
they appear sensitive to inhibitory influences of age (with the
majority of IHD patients .50 yrs old), disease status (most IHD
patients suffer co-morbidities of obesity/dyslipidemia, diabetes,
and/or hypertension), and common pharmaceuticals (almost all
IHD patients are on ß-blockers, statins, ACE inhibitors or
angiotensin II receptor blockers [4]. These factors may explain
modest outcomes from clinical trials of conditioning stimuli [3].
Experimental SLP on the other hand engages unique signaling
which may be resistant to these inhibitory influences [14,15], and
indeed is effective in aged myocardium [13]. While SLP induction
is wortmannin-sensitive [15], implicating PI3K, whether this
reflects a role in phospho-dependent signal transduction, activa-
tion of mRNA translation, and/or regulation of gene transcription
is not known. Certainly the resulting phenotype is unique, I-R
tolerance being independent of PI3K/Akt, NOS, mTOR, KATP
channel and MEK/MAPK activation [14].
Array analysis reveals SLP significantly alters the cardiac
transcriptome, though consistent with novel signaling involvement
[14], this does not involve modulation of canonical protective
paths or molecules (eg. RISK signaling elements, NOS) [16], anti-
oxidants, or major determinants of cell death/apoptosis. Rather,
SLP induces unconventional transcriptional changes, including
shifts in mediators of inflammation/immunity, sarcomere func-
tion, and cardiovascular growth and development (Figures 3 and
4, Table S1). Intriguingly, this response exhibits features similar
to those arising with cardioprotective exercise [17], itself attributed
to OR-dependent signaling [18,19]. Both SLP and voluntary-
Figure 1. Cardioprotective effects of OR-dependent SLP. Data are shown for contractile recoveries and cell death following 25 min ischemia
and 45 min reperfusion in isolated hearts from placebo vs. SLP treated mice (n= 8 per group). Shown are recoveries of left ventricular developed
pressure (% of baseline) and left ventricular end-diastolic pressure (mmHg), together with total post-ischemic washout of cellular LDH. Values are
mean6S.E.M. *, P,0.05 vs. Placebo.
doi:10.1371/journal.pone.0072278.g001
Figure 2. Relationship between transcript and protein expres-
sion changes for cardiac MYH7 and ANP. Data are shown for
myocardial: A) Myh7 and MYH7 transcript and protein levels,
respectively; and B) Nppa and ANP transcript and protein levels,
respectively (n= 6 per group). ND; not detected (MYH7 was un-
detectable in the placebo group; ANP was un-detectable in the
cytosolic fraction). Values are mean6S.E.M. *, P,0.05 vs. Placebo.
doi:10.1371/journal.pone.0072278.g002
Opioid Preconditioning and Cardiac Gene Expression
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running generate predominant mRNA repression vs. induction,
and modify transcripts involved in inflammation/immunity and
sarcomeric function.
Transcripts Up-Regulated in SLP Hearts
Data in Figure 1 highlight powerful protection against
dysfunction and cell death with SLP, a persistent stress-resistance
induced by several days of OR agonism [15]. This pattern
implicates protein expression changes rather than or additional to
post-translational regulation. Only a small set of transcripts was
induced by SLP, the majority being repressed (Table S1). Several
induced transcripts may contribute to I-R tolerance, including a
novel suite of sarcomeric genes (Myh7, Mybpc3, Myom2, Des),
together with potentially protective Nppa and Nppb.
Sarcomeric elements. Myh7 was the most highly induced,
with encoded ß-myosin heavy chain protein also elevated
(Figure 2). There are no prior reports of OR (or ischemic)
regulation of this protein, which is considered a marker of
pathological hypertrophy (reflecting expression of a fetal gene
program). Nonetheless, a solely pathological function for the
protein has recently been challenged [20], and is contrary to
improved cardiac efficiency [21] and Ca2+ homeostasis [22] with
ß-myosin heavy chain expression. Pronounced induction may thus
benefit hearts, reducing the effects of I-R on 2 key outcome
determinants - contractile efficiency and Ca2+ handling.
Transcript for myosin-binding protein C (Mybpc3), a critical
regulator of cardiac function, was also induced. Myosin-binding
protein C stabilizes thick filaments and regulates actomyosin
ATPase activity. Dysregulation leads to dilated and hypertrophic
cardiomyopathies, with phospho-dependent degradation poten-
tially contributing to I-R injury [23]. Induction has not been
previously reported in protected phenotypes, yet could limit
cardiac I-R injury, protect sarcomeric function, and together with
ß-myosin heavy chain improve contractile efficiency.
Induced Myom2 and Des may additionally preserve sarcomere
function. Myomesin-2 is the primary myosin M-band cross-linking
protein, and binds titin in a complex with obscurin/obs1. The
protein is key to normal function, as evidenced by associations
between heart failure and low expression. Since titin is a critical I-
R sensitive sarcomere element [24], up-regulated myomesin-2
may mitigate against titin dysfunction (and is also increased with
protective exercise [17]). Up-regulated desmin (Des) connects
myofibrils to each other and the sarcolemma, controls mitochon-
drial proximity to myofibrils, and maintains myocyte structure and
interactions at Z-disks/intercalated disks. Evidence indicates
degradation of desmin may contribute to cardiac I-R injury
[25]. Novel up-regulation may thus be protective. Collectively,
induction of this suite of key sarcomeric genes may protect against
I-R damage, with reduced desmin and myosin-binding protein C
already implicated in I-R injury, while roles for ß-myosin heavy
chain and myomesin-2 warrant further study.
Natriuretic peptides. Transcripts for atrial natriuretic pep-
tide (ANP) and brain natriuretic peptide (BNP) - Nppa and Nppb,
respectively - were induced with SLP. There are no prior reports
Table 2. The top functional gene groupings sensitive to SLP induction in normoxic myocardium.
Molecular and Cellular Functions P-Value Range No. of Genes
Cell-to-Cell Communication and Interaction 2.48E-23-2.25E-05 51
Cellular Movement 1.61E-20-2.25E-05 43
Antigen Presentation 9.5E-16-1.69E-05 31
Cellular Development 5.97E-14-2.62E-05 51
Cellular Function and Maintenance 6.79E-13-1.13E-05 35
Cellular Growth and Proliferation 2.82E-12-2.62E-05 59
Cell Death 1.09E-10-2.31E-05 53
Cell Signaling 7.27E-10-1.29E-05 24
Molecular Transport 7.27E-10-2.2E-05 27
Physiological System Development and Function P-Value Range No. of Genes
Hematological System Development and Function 1.61E-20-2.58E-05 52
Immune Cell Trafficking 1.61E-20-2.58E-05 42
Tissue Development 2.54E-15-2.58E-05 50
Lymphoid Tissue Structure and Development 8.17E-15-1.16E-05 23
Tissue Morphology 1.25E-14-1.81E-05 35
Disease and Disorders P-Value Range No. of Genes
Inflammatory Response 1.61E-20-2.58E-05 49
Immunological Disease 7.27E-17-1.84E-05 46
Connective Tissue Disorders 1.18E-13-2.47E-05 39
Inflammatory Disease 1.18E-13-2.47E-05 50
Skeletal and Muscular Disorders 1.18E-13-2.47E-05 52
Functional groupings of transcripts differentially modified by SLP in normoxic tissue (also shown are P-values, and numbers of involved genes). Groupings from IPA
analysis are categorized into molecular and cellular functions, physiological system development and function, and disease and disorder (complete functional gene
grouping data can be found in Table S3).
doi:10.1371/journal.pone.0072278.t002
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of OR-dependent control of cardiac ANP/BNP expression,
though the secretion of ANP may be enhanced by ORs [26–28].
Surprisingly, ANP/BNP involvement in pre- or post-conditioning
has not been tested, despite increased secretion with brief ischemia
and reduced I-R injury with exogenously applied peptide [29–31].
ANP and BNP appear to limit cell damage via cGMP/PKG
signals, NO and KATP channels, and modulation of SR Ca
2+
handling [31,32]. Curiously, despite Nppa induction here we did
not detect changes in ANP protein (Figure 2). The basis for these
differing responses is unclear. Cardiac ANP is largely restricted to
secretory granules, secretion leading to membrane-receptor and
cGMP-dependent protection. It is possible SLP enhances both
ANP expression and subsequent secretion, since opioidergic
stimuli (including morphine and m and k-OR agonists) increase
cardiac ANP secretion [26–28], which can be temporally
dissociated from Nppa expression [26]. Potential protection via
SLP-dependent ANP/BNP expression is consistent with impaired
I-R tolerance in mice lacking the natriuretic peptide receptor
guanylyl cyclase-A [33]. Furthermore, cardioprotection with
prolonged oxytocin is associated with ANP expression [34], and
post-ischemic Nbbp correlates with I-R tolerance in a model of
epoxyeicosatrienoic acid mediated protection [35]. Nonetheless,
mechanistic involvement of the peptides in these and other
protective responses remains to be established.
Other induced transcripts. Up-regulated Csda encodes
cold-shock domain protein A (or OxyR), a redox-sensitive
transcriptional controller of anti-oxidants and cellular stress
responses [36]. Induction has not been reported in protected
states, yet may promote myocardial I-R tolerance. Up-regulated
Ptgds encodes prostaglandin D2 synthase, involved in synthesis of
prostaglandin D2. Induction prevents cardiovascular injury via
anti-inflammatory effects [37], protects against platelet aggrega-
tion, and limits growth of vascular smooth muscle cells [38], effects
that could contribute to I-R resistance in vivo. The function of
induced Mpv17 is poorly understood, though there is evidence this
inner mitochondrial membrane protein may regulate mtDNA
copy number and longevity [39]. Tfrc encodes the transferrin
receptor, which contributes to iron handling and could facilitate
iron-dependent oxidative stress. However, there is no strong link
between iron handling and cell damage in myocardial infarction.
Transcripts Repressed in SLP Hearts
The majority of SLP-sensitive transcripts were repressed (Table
S1). Predominant transcript repression has also been observed in
I-R resistant hearts from exercised animals [17]. Most repressed
transcripts were involved in inflammation/immunity, supporting
suppression of inflammation in I-R resistant tissue, again
consistent with anti-inflammatory transcriptional patterns with
Table 3. Functional gene networks modified during SLP induction in normoxic myocardium.
ID Top Functions Molecules In Network Score Focus
Molecules
1 Cellular Movement,
Hematological System
Development and Function,
Immune Cell Trafficking
C8,C/ebp,CCL4,CCL7,CCL9,CCL3L3,CD86,CHEMOKINE,CORO1A,CXCL2,CXCL3,CXCL6,EMR1,Ferritin,
HAMP,HLA-DR,Ifn,IFN alpha/beta,Ifn gamma,Ikk (family),IL-1R,IL12 (family),IRAK,MIP1,
NFkB (complex),NfkB-RelA,NFKBID,PF4,RSAD2,SELPLG,SLC40A1,TFRC,Tlr,TLR2,Tnf
32 18
2 Antigen Presentation,
Inflammatory Response,
Immunological Disease
ALT,C1q,C1QB,CD74,Cebp,CH25H,CLEC6A,CPT2,CTSC,CYP19,FCER1G,Gm-csf,GUCY,H2-a,HDL,
HLA-DQ,HLA-DQA1,HLA-DQB1,HLA-DRB1,IgG2a,IL23,IL1/IL6/TNF,LGALS4,LYVE1,MHC,MHC Class II
(complex),Mhc2 Alpha,NME3,PLIN4,PLK3,SAA,SAA1,Sphk,TLR2/3/4/9,TNF
31 17
3 Cardiovascular Disease,
Infectious Disease,
Inflammatory Disease
ACTG2 (includes EG:72),Adaptor protein 2,AKAP12,Alp,Angiotensin II receptor type 1,Calcineurin
A,CCL2,CCL13,Ck2,Collagen(s),CYR61,DAB2,EGR1,EGR3,Fibrinogen,Focal adhesion kinase,Ikb,IKK
(complex),IL1B,Integrin,Laminin,Lfa-1,Mmp,MYBPC3,N-cor,Pak,Pdgf,Pdgf Ab,PDGF
BB,PTGDS,SERPINA3,SOCS3,STAT,STAT5a/b,STC1
24 14
4 Cardiovascular System
Development and Function,
Tissue Morphology, Lipid
Metabolism
26s Proteasome,ANGPTL4,CENPE,CES1 (includes
EG:1066),CFD,cholesterol,
COMP,CRYAB,DES,DNAJB1,DNAJB4,DSG2,EPAS1,ERBB2,FBP2,GBP5,H6PD,HMGCS2,hydrogen
peroxide,INS1,LAPTM5,ME1,MPV17,MRC1L1,MYOM2,NNMT,
PDPN,PFKFB3,PLIN4,progesterone,SDPR,TACC2,TGFB1,TOM1L2,Ubiquitin
21 13
5 Hematological System
Development and Function,
Hematopoiesis, Lymphoid
Tissue Structure and
Development
AMPK,CD83,Cdc2,Cyclooxygenase,Elastase,Fcer1,GADD45G,Growth
hormone,Hsp27,Hsp70,IFI16,IFI27L2,IFITM1,IFN Beta,Ifnar,Ige,IL1,IL6,IL12 (complex),IRG,JAK,
Ldh,LDL,NfkB1-RelA,Nos,NPC1,P38 MAPK,RCAN1,SELE,SELP,Sod,SYK/ZAP,TLR2/TLR4,UCP3,VCAM1
19 12
6 Drug Metabolism, Lipid
Metabolism, Small Molecule
Biochemistry
ABRA,BCL2A1,BCR,C3,Calcineurin protein(s),Calpain,Caspase,Caspase 3/7,CD72,CFP,CSDA,Cyclin
A,DUSP1,Endothelin,Eotaxin,ERK1/2,GSTA3,HERPUD1,Iga,Igm,IL1A,Immunoglobulin,JINK1/2,MAP2K1/
2,NPPA,NPPB,p70 S6k,Pi3-kinase,PLA2,Pld,Pro-inflammatory Cytokine,Raf,Rar,Sapk,Tgf beta
19 12
7 Lipid Metabolism, Small
Molecule Biochemistry,
Embryonic Development
ACTB,ADCY,Akt,ANGPTL4,Ap1,CD3,Creb,Cyclin E,EGR2,ERK,Erm,Estrogen Receptor,F
Actin,FOS,FOSL2,FSH,hCG,HMOX1,Hsp90,Insulin,JUN/JUNB/JUND,Lh,Mapk,Mek,Nfat (family),NGF,p85
(pik3r),Pka,Pkc(s),PPP1R15A,RAB8B,Ras,Ras homolog,TCR,Vegf
10 8
8 Protein Degradation, Protein
Synthesis, Organ
Morphology
Actin,ADAMTS4,AOX1,CD74,CLPX,CNDP2,Collagen type I,CTRL,FAP,FCGR1C,GUK1,IFITM3,IgG,IgG1,
IGg-Rheumatoid factor,IMMP2L,Interferon alpha,Jnk,KRAS,leukotriene
D4,LGMN,MMP13,MMRN1,MYH7,PDK4,PEPD,peptidase,PEROXIDASE,PI3K,PREP,RNA polymerase
II,SERPINB7,SPCS3,SPPL2B,Tni
8 6
9 Cell Cycle, Gene Expression,
Cellular Growth and
Proliferation
AKAP12,ASF1B,BAZ2A,BRD2,CBR2,CD69,CHFR,DIO1,DOT1L,ELP2,ELP3 (includes
EG:55140),ERCC6,G6PD,Gcn5l,Hat,HIRA,Histone h3,Histone
h4,HPSE,HRAS,ING1,JMJD6,KIR3DL1,MCM4,MGMT,NOC2L,PELP1,SH2D3C,SLAMF9,SMN2,SOX5 (includes
EG:6660),THAP7,VRK1,ZBTB5,ZBTB7A
3 3
doi:10.1371/journal.pone.0072278.t003
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exercise [17]. Additionally, a number of stress-response genes were
repressed by SLP (Table S1).
Inflammation/immunity. Transcripts involved in inflam-
mation/immunity, including interleukins, chemokines/cytokines
and their receptors, and other immune modulators, were down-
regulated (Table S1). A number of these changes may be relevant
to I-R tolerance. Ccl2 (MCP-1) was one of the most repressed, and
is involved in monocyte invasion during I-R [40]. Inhibition of
MCP-1 thus protects the heart, reducing monocyte infiltration and
inflammation [41]. MCP-1 additionally mediates myocyte death
via ER stress [42]. Repression of MCP-1 and other pro-
inflammatory chemoattractants such as Cxcl3, Ccl9/MCP-5,
Ccl4/MIP-1ß, and Ccl7/MCP-3 may thus be relevant to I-R
tolerance, particularly in vivo. Indeed, Ccl7 exaggerates inflamma-
tory injury in heart [43]. The cytokine TNFa is a well-established
mediator of inflammation, cell death and I-R injury, and
repression of Tnf together with pro-inflammatory, pro-apoptotic
and cardiodepressant Il1ß and Il6, may also limit inflammation
and cell damage during I-R.
Endoplasmic Reticulum Stress-Response (ERSR)
transcripts. A significant number of repressed transcripts are
involved in or targeted by the ERSR. While generally beneficial,
the ERSR can also promote apoptosis during severe or sustained
insult, including myocardial I-R [44]. Known ERSR genes Dnajb1,
Socs3 and Herpud1 were repressed by SLP, together with putative
ERSR genes Il6, Gadd45g and Rcan1. As noted above, MCP-1 also
up-regulates myocyte ER stress genes, such as Dnajb1, promoting
ER-dependent apoptosis [42]. Repression of Dnajb1 and MCP-1
may thus counter death signaling. Reductions in Socs3, a feedback
inhibitor of JAK-Stat, can also limit infarction and remodeling
[45]. Repression of Il6 may further contribute since Il6 induction
by BNIP3 in hypoxia/ischemia may mediate infarction and
pathological remodeling.
Other repressed transcripts. Other down-regulated tran-
scripts are relevant to SLP protection. Pdk4, encoding pyruvate
dehydrogenase kinase 4 (PDK4), was the most repressed in SLP
hearts (Table S1). PDK4 phosphorylates and inactivates pyruvate
dehydrogenase, with repression favoring a substrate switch from
fatty acid to glucose metabolism, a shift known to protect against I-
R injury [46,47]. While there are no reported associations between
Pdk4 expression and cardioprotection, inhibition of PDK does
protect ischemic myocardium [48], supporting benefit via SLP-
dependent Pdk4 repression. Repression of Mmp13 may also
improve post-ischemic outcomes since MMP-13 is involved in
post-infarction fibrosis and detrimental ventricular remodeling.
SLP Modulation of Post-Ischemic Transcripts
While ,1/3 of transcripts modified by SLP in post-ischemic
tissue were similarly altered prior to ischemia, 46 were specific to
post-ischemic tissue (Table S2). These include up-regulated
transcripts for regulators of cardiac growth and function (xin
actin-binding repeat containing 1 and ankyrin repeat domain 1 -
repression of the latter linked to cardiac apoptosis), anti-oxidants
and cell-stress proteins (microsomal glutathione S-transferase 3,
glutathione S-transferase m1 and m2, clusterin), cell-signaling
elements (dual specificity phosphatase 6, connector enhancer of
kinase suppressor of Ras 1, GTP cyclohydrolase I feedback
Figure 3. The top 2 networks modified by SLP in normoxic myocardium (networks 1 and 2, both involved in immunity/
inflammation). Shown are the 2 most modified gene networks in SLP hearts. Network 1 is involved in hematological development and cellular
movement/immune cell trafficking; Network 2 in antigen presentation and immune/inflammatory function. Transcripts are color-coded according to
expression changes (green, up-regulated; red, down-regulated). Grey highlights molecules present in the dataset (FDR#5%) that did not meet the
$1.3-fold cut-off criteria. White indicates predicted molecules computationally incorporated into networks based on evidence within the IPA
knowledge base. Lines between molecules indicate direct molecular connections.
doi:10.1371/journal.pone.0072278.g003
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Figure 4. The top 2 cardiovascular-related networks modified by SLP in normoxic myocardium (networks 3 and 4). Shown are the 3rd
and 4th most modified gene networks in SLP hearts. Network 3 is involved in cardiovascular, inflammatory and immune diseases; Network 4 in
cardiovascular system development. Transcripts and interactions are coded as outlined in Figure 3.
doi:10.1371/journal.pone.0072278.g004
Table 4. The top functional gene groupings sensitive to SLP in post-ischemic myocardium.
Molecular and Cellular Functions P-Value Range No. of Genes
Cell-To-Cell Signaling and Interaction 7.10E-13 - 2.00E-03 33
Cellular Movement 3.75E-08 - 2.52E-03 26
Antigen Presentation 5.52E-08 - 2.37E-03 18
Cell Signaling 5.72E-08 - 2.50E-03 19
Small Molecule Biochemistry 5.72E-08 - 2.52E-03 29
Physiological System Development and Function P-Value Range No. of Genes
Hematological System Development and Function 2.80E-10 - 2.53E-03 31
Immune Cell Trafficking 5.80E-10 - 2.52E-03 26
Nervous System Development and Function 5.03E-08 - 5.88E-04 8
Endocrine System Development and Function 1.85E-07 - 2.52E-03 7
Tissue Development 5.43E-07 - 2.52E-03 31
Disease and Disorders P-Value Range No. of Genes
Inflammatory Response 4.70E-10 - 2.52E-03 31
Inflammatory Disease 1.13E-09 - 2.52E-03 31
Renal and Urological Disease 1.51E-09 - 1.77E-03 18
Immunological Disease 3.80E-09 - 2.52E-03 19
Cardiovascular Disease 6.63E-09 - 2.53E-03 22
Functional groupings of transcripts differentially modified by SLP in post-ischemic tissue (also shown are P-values, and numbers of involved genes). Groupings from IPA
analysis are categorized into molecular and cellular functions, physiological system development and function, and disease and disorders (complete functional gene
grouping data can be found in Table S4).
doi:10.1371/journal.pone.0072278.t004
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regulator), metabolic enzymes (glucokinase or hexokinase-4,
NADH dehydrogenase 1ß sub-complex 4), and tumor necrosis
factor receptor superfamily member 12A (TWEAK receptor,
involved in maladaptive remodeling and inflammatory disease).
Transcripts repressed in post-ischemic tissue included Txnip, which
inhibits thioredoxin and is an important determinant of myocar-
dial I-R damage not previously linked to cardioprotective stimuli.
Ucp2 was also repressed, which may protect against oxidative
stress. A number of these responses, together with common pre-
and post-ischemic responses outlined above (eg. induced Myh7,
Mybpc3, Nppa, Nppb; repressed Pdk4, Ccl2, Ccl4, Il1ß, Ccl7) could
well contribute to improvements in post-ischemic infarct develop-
ment with SLP.
SLP also repressed post-ischemic expression of a cluster of
stress-responsive transcripts, consistent with enhanced I-R toler-
ance (Figure 1). Post-ischemic expression of Hsph1, Hspa1a,
Serpinh1, Hspd1, and Hsp90aa1 was reduced in SLP hearts (Table
S2). As the cells molecular response to insult determines stress-
signaling activation (rather than the nature of the external insult
itself), reduced expression of such transcripts may well reflect a
more robust intracellular milieu and intrinsic resistance to I-R in
SLP hearts.
Conclusions
Consistent with a unique signaling profile [14], SLP does not
transcriptionally modify canonical pathways/mediators of cell
survival and cardioprotection, but regulates expression of genes
involved in inflammation/immunity, contractile/sarcomeric func-
tion, cardiac growth and development, and stress-signaling. The
novel SLP response offers distinct advantages as a candidate for
development of adjunctive cardioprotection (albeit currently
limited to pre-ischemic intervention), including preserved efficacy
in aged myocardium [13] where conventional stimuli may fail [4].
Though able to limit infarction up to 40% if implemented within a
60–90 min window from symptom onset [16], effects of reperfu-
sion therapy remain variable: in as many as half of patients, 50%
of at-risk myocardium may not be salvaged, while in a quarter up
to 75% infarction may still occur [49]. Unfortunately, optimal
timing of reperfusion is frequently unrealized, with reports of
delays of 4–5 hrs from symptom onset to reperfusion for US
patients [50,51], and in urban Australian hospitals [52]. These
data emphasize the need for adjunctive cardioprotection that may
be applied prior to, with or after reperfusion to improve outcomes,
broaden the window for reperfusion and limit progression to
failure. The present data, highlighting shifts in inflammation/
immunity and sarcomere structure/function with SLP, suggest
that modulation of inflammatory signaling and sarcomeric
integrity may be valuable in generating sustained I-R tolerance.
Future work is warranted in identifying the functional relevance of
these novel gene expression patterns in governing myocardial
resistance to injurious stimuli.
Materials and Methods
All studies were approved by and performed in accordance with
the guidelines of the Animal Ethics Committee of Griffith
University, which is accredited by the Queensland Government,
Department of Primary Industries and Fisheries under the
guidelines of ‘‘The Animal Care and Protection Act 2001, Section
757’’.
Animals and Experimental Design
Mature male C57Bl/6 mice aged 10–14 weeks (n=8 for
functional studies; n=6 for gene and protein expression analyses)
were briefly anesthetized with halothane, a small incision made at
the base of the neck, and placebo or 75-mg morphine pellets
Table 5. Functional gene networks modified by SLP in post-ischemic myocardium.
ID Top Functions Molecules In Network Score Focus
Molecules
1 Lipid Metabolism, Small
Molecule Biochemistry,
Cellular Function and
Maintenance
Alp,AMPK,CLU,Cyclooxygenase,Cytochrome c,DNAJB1,DUSP6,Fcer1,glutathione transferase,
Growth hormone,GST,GSTM1,GSTM2,Hsp27,Hsp70,HSP90AA1,HSPA1A,IGFBP5, IgG1,IgG2a,IL1,IL6,
JINK1/2,LDL,LGALS4,MGST3,NPC1,PLIN2,SAA,Serine Protease, SERPINA3,Sod,STAT,UCP2,UCP3
30 16
2 Antigen Presentation,
Inflammatory Response,
Immunological Disease
ANKRD1,CCL4,CCL7,CCL3L3,CD74,CHEMOKINE,CORO1A,Endothelin,Gm-csf,HLA-DQ,HLA-DQA1,
HLA-DQB1,HLA-DR,HLA-DRB1,IFN alpha/beta,IFN Beta,Ifn gamma,Ifnar,IFNB1,IL-1R,IL12 (complex),IL12
(family),Immunoglobulin,LY6C1,MHC,MHC Class II (complex),Mhc2 Alpha,NFkB (complex),NfkB-RelA,
NfkB1-RelA,Pro-inflammatory Cytokine,RSAD2,Tlr,TNFRSF12A,TXNIP
25 14
3 Hematological System
Development and Function,
Hematopoiesis, Organismal
Development
ANGPT1,ATP5S,C22ORF28,C5ORF13,CBR2,CCDC80,
dimethylglycine,EPO,EWSR1,FYCO1,HNF4A,HRAS,HSPH1,HTT,KNDC1 (includes
EG:85442),KRAS,LAPTM5,MYH7, NDUFB2,NDUFB4,NME3,
NRN1,PDK4,RAPH1,RASL11B,RTP3,SEC11C,SLC25A22,SLC44A2,SLFN12L,TLN1,TNF,TRIM15 (includes
EG:89870),ZBTB11,ZNF318 (includes EG:24149)
25 14
4 Nucleic Acid Metabolism,
Small Molecule Biochemistry,
Endocrine System
Development and Function
ABRA,Akt,C3,C4A,CCL2,CDH16,Collagen(s),Cyclin A,Cyclin E,EIF4EBP1,ERK,ERK1/2,Estrogen Receptor,
Focal adhesion kinase,HES1,HMOX1,HSPD1,Ige,Igm,IL1B,Insulin,MAP2K1/2, NGF,NPPA,NPPB,
p70 S6k,p85 (pik3r),Pdgf,PDGF BB,Pi3-kinase,PI3K,Pld,PTGDS,Ras,STAT5a/b
22 13
5 Cell-To-Cell Signaling and
Interaction, Cellular
Movement, Immune Cell
Trafficking
ABAT,ACPP,ANKS1A,ARC,C11ORF82,CHAC1,CRK,CXCL6,CXCL10,ERBB2,GBP1 (includes
EG:14468),GCHFR,H6PD,HNRNPK,hydrogen peroxide,IFI30,IFI47,IFIT5,IFITM2,IFITM3,IFNG,
IL4I1,IRF6,IRGM2,LAMP1,MIRN324,MPV17,MRC1L1,MYBPC3,PRDX2,RBMX,SERPINH1,
SLCO2B1,SP110,ZFX
16 10
6 Carbohydrate Metabolism, Cell
Morphology, Cellular Assembly
and Organization
ANGPTL4,Ap1,B2M,Ck2,CNKSR1,EHD4,Fibrinogen,FSH,GCK,hCG,Histone h3,Histone h4, HSPG2
(includes EG:3339),IgG,Ikb,Interferon alpha,Jnk,KLRA17,Lh,LYVE1,Mapk,MHC Class I
(complex),Mmp,MMP13,Nfat (family),P38 MAPK,Pkc(s),Ras homolog,RGS5,RNA polymerase
II,Rxr,SERPINB7,Tgf beta,Tnf,Vegf
11 8
doi:10.1371/journal.pone.0072278.t005
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(National Institute of Drug Abuse, Bethesda, MD) were inserted
into the dorsal subcutaneous space before closure with 9-mm
wound clips, as outlined previously [12,15]. Pellets were left in
place for 5 days before analysis of cardiac I-R tolerance ex vivo and
analysis of cardiac gene expression.
Ex Vivo Myocardial I-R
Mice were anesthetized with sodium pentobarbital (60 mg/kg)
and hearts excised and perfused in a Langendorff mode as
described previously [15]. After 30 min stabilization control
(placebo) and SLP hearts were subjected to either 25 min of
global normothermic ischemia and 45 min of aerobic reperfusion,
or time-matched normoxic perfusion. Protection afforded by SLP
was evaluated by assessing post-ischemic recoveries of left
ventricular end-diastolic pressure and developed pressures, with
total washout of myocardial LDH throughout the reperfusion
period employed as an indicator of cellular disruption/oncosis
(LDH content assayed enzymatically as outlined previously [15]).
On completion of experiments hearts were stored in cold RNAlater
solution to protect RNA integrity and expression levels prior to
ventricular dissection and RNA extraction.
RNA Isolation and Microarray Analysis
Microarray analysis was performed in a manner similar to that
outlined previously [17]. Atrial and vascular tissue was removed
and left ventricular myocardium dissected from each heart,
homogenized in TRIzolH reagent (Invitrogen, Carlsbad, CA,
USA), and total RNA isolated according to manufacturer’s
guidelines. Total RNA was further purified using RNeasy spin
columns (Qiagen, Maryland, USA). The RNA yield and integrity
were determined using a NanoDrop ND-1000 (NanoDrop
Technologies, Wilmington, DE, USA) and a 2100 Bioanalyzer
(Agilent Technologies, Forest Hills VIC, Australia), respectively.
RNA integrity (RIN) scores were $8.0 in each sample.
Microarray experiments were performed at the IMB Micro-
array Facility (University of Queensland) according to standard
protocols. In brief, 0.5 mg of total RNA was used to synthesize
biotinylated amplified RNA (aRNA) using an Illumina TotalPrep
RNA amplification kit (Illumina Inc., La Jolla, CA, USA). Samples
of aRNA (1.5 mg) were fragmented and hybridized (n=6 per
group) to MouseWG-6 v1.1 BeadChips (Illumina Inc., La Jolla,
CA, USA). Following hybridization, microarrays were washed and
stained with streptavidin-Cy3 prior to scanning on an Illumina
BeadStation Scanner. Data values with detection scores were
compiled using BeadStudio v2.3.41 (Illumina Inc., La Jolla, CA,
USA). The data discussed here were deposited into NCBI’s Gene
Expression Omnibus (GEO). Data are accessible through GEO
Series accession number GSE39407 at http://www.ncbi.nlm.nih.
gov/geo/.
Array Data Analysis
Microarray expression data were variance stabilized and robust
spline normalized using the ‘lumi’ package in R/BioConductor
(http://www.r-project.org/) [53]. Data were filtered to include
only transcripts with detection scores $0.99 on $2 arrays before
statistical analysis via TIGR MeV 4.0 software (13,335 bead types
passed these criteria). The Significant Analysis of Microarrays
(SAM) algorithm was used to correct for multiple comparisons and
non-parametrically identify differentially expressed genes [54].
After multiclass SAM analysis, transcripts with fold-changes of
$1.3 and a false discovery rate (FDR) of #5% were classed as
significantly differentially expressed. These genes were functionally
annotated via Ingenuity Pathway Analysis (IPA) (v8.7; IngenuityH
Systems, Redwood City, CA, USA) to link SLP-sensitive genes in
signal networks based on known molecule interactions and
canonical pathways. IPA was also used to identify the top
biological and molecular themes on the basis of over-representa-
tion analysis. Briefly, the fraction of altered genes within a
canonical path was compared to the fraction of total genes within
that path. Probability of involvement of the respective number of
modified transcripts in the path/network is expressed as a P-value
(with values ,0.05 considered significant).
RT-qPCR Confirmation of Microarray Data
Two-step RT-qPCR, utilizing SYBR Green I, was employed to
confirm differential gene expression of the following 12 transcripts:
Ankrd1, Ccl7, Fos, Hamp, Il6, Myh7, Nppa, Pdk4, Tlr2, Txnip, Vcam1
and Xirp1 (primer details provided in Table S5). Six additional
genes (Actb, Top1, Pgk1, Gapdh, 18S rRNA and Atp5b) were assessed
using GeNorm to determine their usability as reference genes [55].
Following GeNorm assessment, Pgk1 was found to be the most
stable (M=0.04) and therefore served as the endogenous reference
control for all mRNAs assessed via RT-qPCR. Briefly, 1 mg total
RNA was used to synthesize cDNA using the Superscript III First-
Strand Synthesis System (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s protocol. RT-qPCR was
Figure 5. Validation of microarray assay data by RT-qPCR.
Shown are expression changes determined via RT-qPCR and microarray
analysis for: A) SLP vs placebo responses in normoxic myocardium; and
B) SLP vs. placebo responses in post-ischemic myocardium. Data are
expressed as means 6 S.E.M. (n= 6 per group). Linear regression
analysis of these data yielded a significant and strongly positive
correlation (r2 = 0.95): RT-qPCR expression = (1.3516microarray expres-
sion) - 0.047 (the slope factor .1 indicative of a predictably greater
dynamic range for RT-qPCR analysis).
doi:10.1371/journal.pone.0072278.g005
Opioid Preconditioning and Cardiac Gene Expression
PLOS ONE | www.plosone.org 9 August 2013 | Volume 8 | Issue 8 | e72278
performed in a CFX96 Real-Time PCR Detection System (Bio-
Rad, Hercules, CA). The final reaction volume (10 mL) included
5 mL iQ SYBR-Green Supermix (Bio-Rad, Hercules, CA),
100 nM of each primer, and 4 mL of a 1:20 dilution of cDNA.
Optimal qPCR cycling conditions entailed an initial denaturation
at 95uC for 3 min followed by 40 cycles of 95uC for 15 sec/62uC
for 60 sec. After the final PCR cycle, reactions underwent melt
curve analysis to detect non-specific amplicons. All reactions were
performed in triplicate with each plate containing an equal
number of samples from each group, a calibrator control derived
from a pool of all cDNA samples, and a no-template control. PCR
amplification efficiencies (90–110%) for each primer pair were
calculated using a 5-log serial dilution of calibrator sample. PCR
data were analyzed using CFX Manager v1.6 (Bio-Rad, Hercules,
CA). Baseline subtractions and threshold settings above back-
ground were applied to all data. The calibrator sample was used to
normalize inter-assay variations, with the threshold coefficient of
variance for intra- and inter-assay replicates ,1% and ,5%,
respectively. Normalized expression (DDCq) was calculated, with
mRNAs normalized to Pgk1 levels and the calibrator control then
log2-transformed.
Myocardial Protein Expression
To assess the impact of transcriptional changes on protein
expression immunoblot analysis was employed as outlined
previously [14,15] to assess myocardial expression of MYH7 and
ANP, both transcriptionally induced with SLP and implicated in
modulation of cardiac phenotype under other conditions. Briefly, a
sub-set of placebo and SLP hearts (n=6 per group) were removed
from the chest, frozen in liquid N2, and homogenized using a glass
dounce in lysis buffer containing protease and phosphatase
inhibitors. Samples containing 30 mg of protein from either
cytosolic or detergent-soluble membrane fractions were loaded
onto 10% acrylamide gels (equal loading confirmed by Ponceau
staining) and electrophoresed at 150 V for 1.5 hrs. Protein was
transferred to polyvinylidene difluoride membranes and blocked in
5% skim milk powder in Tris-buffered saline with Tween 20
(TBST) for 60 min. Membranes were then incubated with
primary antibody (MYH7 or ANP; 1:1000 dilution, Cell Signaling
Technology Inc., Danvers, MA, USA) overnight at 4uC. Following
3 washes in TBST, membranes were incubated with secondary
antibody and visualized on a ChemiDoc XRS system (Bio-Rad,
Hercules, CA, USA). Protein expression was normalized to values
for placebo hearts for the purposes of comparison.
Statistical Analyses
Unless stated otherwise, physiological and gene expression data
are expressed as means 6 SEM. Statistical approaches to
microarray interrogation are detailed above. Other data were
analyzed using SPSS 18.0 for Windows (SPSS Inc., Chicago, IL).
Comparisons between groups were made via an analysis of
variance (ANOVA), with Tukeys post-hoc test applied where
differences were detected. Significance was accepted for P,0.05.
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